STAT3 and neoplasm: Importantly, the combination inhibited tumor growth and reduced PD-L1 expression by targeting the EGFR/JAK/STAT3 signaling pathway, demonstrating potential to overcome anti-PD1 therapy resistance (Fig. 6).